Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-02-09

AUTHORS

Koichi Kamei, Masao Ogura, Mai Sato, Shuichi Ito, Kenji Ishikura

ABSTRACT

BackgroundInfusion reaction (IR) is defined as an adverse event within 24 h after monoclonal antibody infusion. In non-Hodgkin lymphoma, IR incidence following rituximab treatment is high (77–80%), but there are no data in complicated nephrotic syndrome.MethodsRecords of rituximab infusions in patients with complicated nephrotic syndrome between February 2006 and December 2014 at the National Center for Child Health and Development were reviewed. Rituximab was administered at doses of 375 mg/m2. The severity of IR was evaluated using the Common Terminology Criteria for Adverse Events ver. 4.0.ResultsFor 309 rituximab infusions in 159 patients (male, 110; median age, 12 years), IR was observed in 165 infusions (53.4%). Respiratory symptoms were most common (66% of all events). Ninety-five percent of the IR was observed within 3 h after rituximab infusion initiation. Sixty-eight percent of the events were classified as grade 1 and others classified as grade 2. Only 18% required medical intervention. CD20 cell count in patients with IR was significantly higher than in patients without IR. Incidence of IR was similar in subsequent rituximab treatment after B-cell recovery. Patients who experienced IR at first rituximab treatment were more likely to experience recurrent IR with subsequent treatments compared to those not having IR at initial treatment (odds ratio 3.64; p < 0.001).ConclusionsIn patients with complicated nephrotic syndrome, respiratory symptoms were the major type of IR, mostly observed within 3 h of infusion. Incidence of IR was lower and its severity milder in patients with complicated nephrotic syndrome than those with lymphoma. More... »

PAGES

1013-1018

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00467-018-3900-z

DOI

http://dx.doi.org/10.1007/s00467-018-3900-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100938663

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29426974


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunologic Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nephrotic Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.63906.3a", 
          "name": [
            "Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kamei", 
        "givenName": "Koichi", 
        "id": "sg:person.01316365041.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316365041.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.63906.3a", 
          "name": [
            "Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ogura", 
        "givenName": "Masao", 
        "id": "sg:person.01174574062.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174574062.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.63906.3a", 
          "name": [
            "Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sato", 
        "givenName": "Mai", 
        "id": "sg:person.01060345462.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060345462.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Yokohama City University Graduate School pf Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Pediatrics, Yokohama City University Graduate School pf Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ito", 
        "givenName": "Shuichi", 
        "id": "sg:person.012302533312.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.63906.3a", 
          "name": [
            "Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishikura", 
        "givenName": "Kenji", 
        "id": "sg:person.01112735663.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112735663.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00467-009-1195-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028250994", 
          "https://doi.org/10.1007/s00467-009-1195-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10157-014-1030-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019458362", 
          "https://doi.org/10.1007/s10157-014-1030-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-012-2286-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009853115", 
          "https://doi.org/10.1007/s00467-012-2286-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.thj.6200133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056649401", 
          "https://doi.org/10.1038/sj.thj.6200133"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-007-0329-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002510364", 
          "https://doi.org/10.1007/s00520-007-0329-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02-09", 
    "datePublishedReg": "2018-02-09", 
    "description": "BackgroundInfusion reaction (IR) is defined as an adverse event within 24\u00a0h after monoclonal antibody infusion. In non-Hodgkin lymphoma, IR incidence following rituximab treatment is high (77\u201380%), but there are no data in complicated nephrotic syndrome.MethodsRecords of rituximab infusions in patients with complicated nephrotic syndrome between February 2006 and December 2014 at the National Center for Child Health and Development were reviewed. Rituximab was administered at doses of 375\u00a0mg/m2. The severity of IR was evaluated using the Common Terminology Criteria for Adverse Events ver. 4.0.ResultsFor 309 rituximab infusions in 159 patients (male, 110; median age, 12\u00a0years), IR was observed in 165 infusions (53.4%). Respiratory symptoms were most common (66% of all events). Ninety-five percent of the IR was observed within 3\u00a0h after rituximab infusion initiation. Sixty-eight percent of the events were classified as grade 1 and others classified as grade 2. Only 18% required medical intervention. CD20 cell count in patients with IR was significantly higher than in patients without IR. Incidence of IR was similar in subsequent rituximab treatment after B-cell recovery. Patients who experienced IR at first rituximab treatment were more likely to experience recurrent IR with subsequent treatments compared to those not having IR at initial treatment (odds ratio 3.64; p\u2009<\u20090.001).ConclusionsIn patients with complicated nephrotic syndrome, respiratory symptoms were the major type of IR, mostly observed within 3\u00a0h of infusion. Incidence of IR was lower and its severity milder in patients with complicated nephrotic syndrome than those with lymphoma.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00467-018-3900-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.9337961", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.9341874", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1097267", 
        "issn": [
          "0931-041X", 
          "1432-198X"
        ], 
        "name": "Pediatric Nephrology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "keywords": [
      "complicated nephrotic syndrome", 
      "rituximab treatment", 
      "nephrotic syndrome", 
      "rituximab infusion", 
      "respiratory symptoms", 
      "monoclonal antibody infusion", 
      "Adverse Events ver", 
      "Common Terminology Criteria", 
      "non-Hodgkin lymphoma", 
      "severity of IR", 
      "Terminology Criteria", 
      "ConclusionsIn patients", 
      "infusion reactions", 
      "adverse events", 
      "antibody infusion", 
      "initial treatment", 
      "infusion initiation", 
      "child health", 
      "patients", 
      "grade 2", 
      "cell count", 
      "infusion", 
      "syndrome", 
      "medical interventions", 
      "IR incidence", 
      "grade 1", 
      "incidence", 
      "cell recovery", 
      "subsequent treatment", 
      "treatment", 
      "lymphoma", 
      "symptoms", 
      "percent", 
      "MethodsRecords", 
      "rituximab", 
      "doses", 
      "severity", 
      "intervention", 
      "major types", 
      "National Center", 
      "health", 
      "count", 
      "milder", 
      "events", 
      "initiation", 
      "ver", 
      "m2", 
      "criteria", 
      "recovery", 
      "center", 
      "reaction", 
      "data", 
      "development", 
      "types", 
      "IR"
    ], 
    "name": "Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome", 
    "pagination": "1013-1018", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100938663"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00467-018-3900-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29426974"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00467-018-3900-z", 
      "https://app.dimensions.ai/details/publication/pub.1100938663"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_787.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00467-018-3900-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00467-018-3900-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00467-018-3900-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00467-018-3900-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00467-018-3900-z'


 

This table displays all metadata directly associated to this object as RDF triples.

204 TRIPLES      22 PREDICATES      94 URIs      81 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00467-018-3900-z schema:about N1c3fcac742a042ac8f2bd009708e0d76
2 N3dd0b94ac79242c4a3ae8a9b7a7ba6be
3 N50ccc3078d8b4274948a33ced0e2741d
4 N5e93ecab8e4348318772faff44098c6c
5 N625e8f69446b439eae08816a2dc25be1
6 N806ed1e7f778473396fcb6a145f20309
7 N8df99928650447d5a5613171978e28b8
8 N9d9a7fc761774c0f8c22a62be97670b9
9 anzsrc-for:11
10 anzsrc-for:1103
11 schema:author N99977a8aaebc47b9907ded3bd9b08c44
12 schema:citation sg:pub.10.1007/s00467-009-1195-9
13 sg:pub.10.1007/s00467-012-2286-6
14 sg:pub.10.1007/s00520-007-0329-5
15 sg:pub.10.1007/s10157-014-1030-x
16 sg:pub.10.1038/sj.thj.6200133
17 schema:datePublished 2018-02-09
18 schema:datePublishedReg 2018-02-09
19 schema:description BackgroundInfusion reaction (IR) is defined as an adverse event within 24 h after monoclonal antibody infusion. In non-Hodgkin lymphoma, IR incidence following rituximab treatment is high (77–80%), but there are no data in complicated nephrotic syndrome.MethodsRecords of rituximab infusions in patients with complicated nephrotic syndrome between February 2006 and December 2014 at the National Center for Child Health and Development were reviewed. Rituximab was administered at doses of 375 mg/m2. The severity of IR was evaluated using the Common Terminology Criteria for Adverse Events ver. 4.0.ResultsFor 309 rituximab infusions in 159 patients (male, 110; median age, 12 years), IR was observed in 165 infusions (53.4%). Respiratory symptoms were most common (66% of all events). Ninety-five percent of the IR was observed within 3 h after rituximab infusion initiation. Sixty-eight percent of the events were classified as grade 1 and others classified as grade 2. Only 18% required medical intervention. CD20 cell count in patients with IR was significantly higher than in patients without IR. Incidence of IR was similar in subsequent rituximab treatment after B-cell recovery. Patients who experienced IR at first rituximab treatment were more likely to experience recurrent IR with subsequent treatments compared to those not having IR at initial treatment (odds ratio 3.64; p < 0.001).ConclusionsIn patients with complicated nephrotic syndrome, respiratory symptoms were the major type of IR, mostly observed within 3 h of infusion. Incidence of IR was lower and its severity milder in patients with complicated nephrotic syndrome than those with lymphoma.
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree false
23 schema:isPartOf N3f174ee866284d39a5c370d2b3baf8b1
24 N5d3e1392d36745998a492a55d0962135
25 sg:journal.1097267
26 schema:keywords Adverse Events ver
27 Common Terminology Criteria
28 ConclusionsIn patients
29 IR
30 IR incidence
31 MethodsRecords
32 National Center
33 Terminology Criteria
34 adverse events
35 antibody infusion
36 cell count
37 cell recovery
38 center
39 child health
40 complicated nephrotic syndrome
41 count
42 criteria
43 data
44 development
45 doses
46 events
47 grade 1
48 grade 2
49 health
50 incidence
51 infusion
52 infusion initiation
53 infusion reactions
54 initial treatment
55 initiation
56 intervention
57 lymphoma
58 m2
59 major types
60 medical interventions
61 milder
62 monoclonal antibody infusion
63 nephrotic syndrome
64 non-Hodgkin lymphoma
65 patients
66 percent
67 reaction
68 recovery
69 respiratory symptoms
70 rituximab
71 rituximab infusion
72 rituximab treatment
73 severity
74 severity of IR
75 subsequent treatment
76 symptoms
77 syndrome
78 treatment
79 types
80 ver
81 schema:name Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome
82 schema:pagination 1013-1018
83 schema:productId N0442e346b18c42768e7384c9fc7ea50f
84 N2cc93a0ebdb54bdc9a60f6eaa64a7b79
85 N6f8185e096164126ab55197d95754c15
86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100938663
87 https://doi.org/10.1007/s00467-018-3900-z
88 schema:sdDatePublished 2022-05-10T10:20
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher N1df38f81a2ef4c62bc4a5f242454da32
91 schema:url https://doi.org/10.1007/s00467-018-3900-z
92 sgo:license sg:explorer/license/
93 sgo:sdDataset articles
94 rdf:type schema:ScholarlyArticle
95 N0442e346b18c42768e7384c9fc7ea50f schema:name doi
96 schema:value 10.1007/s00467-018-3900-z
97 rdf:type schema:PropertyValue
98 N1c3fcac742a042ac8f2bd009708e0d76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Immunologic Factors
100 rdf:type schema:DefinedTerm
101 N1df38f81a2ef4c62bc4a5f242454da32 schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 N2cc93a0ebdb54bdc9a60f6eaa64a7b79 schema:name dimensions_id
104 schema:value pub.1100938663
105 rdf:type schema:PropertyValue
106 N3dd0b94ac79242c4a3ae8a9b7a7ba6be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Male
108 rdf:type schema:DefinedTerm
109 N3f174ee866284d39a5c370d2b3baf8b1 schema:issueNumber 6
110 rdf:type schema:PublicationIssue
111 N50ccc3078d8b4274948a33ced0e2741d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Rituximab
113 rdf:type schema:DefinedTerm
114 N5d3e1392d36745998a492a55d0962135 schema:volumeNumber 33
115 rdf:type schema:PublicationVolume
116 N5e93ecab8e4348318772faff44098c6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N625e8f69446b439eae08816a2dc25be1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Nephrotic Syndrome
121 rdf:type schema:DefinedTerm
122 N6f8185e096164126ab55197d95754c15 schema:name pubmed_id
123 schema:value 29426974
124 rdf:type schema:PropertyValue
125 N728d3f04a915426c97d7df8b958877d3 rdf:first sg:person.01112735663.13
126 rdf:rest rdf:nil
127 N806ed1e7f778473396fcb6a145f20309 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Child
129 rdf:type schema:DefinedTerm
130 N8be206e4b3b743a88606f25ee18c8e8a rdf:first sg:person.012302533312.63
131 rdf:rest N728d3f04a915426c97d7df8b958877d3
132 N8df99928650447d5a5613171978e28b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Female
134 rdf:type schema:DefinedTerm
135 N99977a8aaebc47b9907ded3bd9b08c44 rdf:first sg:person.01316365041.17
136 rdf:rest Nacde3bf3927843d4b83eba6b22f2321c
137 N9d9a7fc761774c0f8c22a62be97670b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Child, Preschool
139 rdf:type schema:DefinedTerm
140 Nacde3bf3927843d4b83eba6b22f2321c rdf:first sg:person.01174574062.16
141 rdf:rest Nb16fd67304b94ff69ac1b3dd4c5b8c97
142 Nb16fd67304b94ff69ac1b3dd4c5b8c97 rdf:first sg:person.01060345462.48
143 rdf:rest N8be206e4b3b743a88606f25ee18c8e8a
144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
145 schema:name Medical and Health Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
148 schema:name Clinical Sciences
149 rdf:type schema:DefinedTerm
150 sg:grant.9337961 http://pending.schema.org/fundedItem sg:pub.10.1007/s00467-018-3900-z
151 rdf:type schema:MonetaryGrant
152 sg:grant.9341874 http://pending.schema.org/fundedItem sg:pub.10.1007/s00467-018-3900-z
153 rdf:type schema:MonetaryGrant
154 sg:journal.1097267 schema:issn 0931-041X
155 1432-198X
156 schema:name Pediatric Nephrology
157 schema:publisher Springer Nature
158 rdf:type schema:Periodical
159 sg:person.01060345462.48 schema:affiliation grid-institutes:grid.63906.3a
160 schema:familyName Sato
161 schema:givenName Mai
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060345462.48
163 rdf:type schema:Person
164 sg:person.01112735663.13 schema:affiliation grid-institutes:grid.63906.3a
165 schema:familyName Ishikura
166 schema:givenName Kenji
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112735663.13
168 rdf:type schema:Person
169 sg:person.01174574062.16 schema:affiliation grid-institutes:grid.63906.3a
170 schema:familyName Ogura
171 schema:givenName Masao
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174574062.16
173 rdf:type schema:Person
174 sg:person.012302533312.63 schema:affiliation grid-institutes:grid.268441.d
175 schema:familyName Ito
176 schema:givenName Shuichi
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63
178 rdf:type schema:Person
179 sg:person.01316365041.17 schema:affiliation grid-institutes:grid.63906.3a
180 schema:familyName Kamei
181 schema:givenName Koichi
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316365041.17
183 rdf:type schema:Person
184 sg:pub.10.1007/s00467-009-1195-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028250994
185 https://doi.org/10.1007/s00467-009-1195-9
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/s00467-012-2286-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009853115
188 https://doi.org/10.1007/s00467-012-2286-6
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/s00520-007-0329-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002510364
191 https://doi.org/10.1007/s00520-007-0329-5
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/s10157-014-1030-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019458362
194 https://doi.org/10.1007/s10157-014-1030-x
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/sj.thj.6200133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056649401
197 https://doi.org/10.1038/sj.thj.6200133
198 rdf:type schema:CreativeWork
199 grid-institutes:grid.268441.d schema:alternateName Department of Pediatrics, Yokohama City University Graduate School pf Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan
200 schema:name Department of Pediatrics, Yokohama City University Graduate School pf Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Kanagawa, Japan
201 rdf:type schema:Organization
202 grid-institutes:grid.63906.3a schema:alternateName Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan
203 schema:name Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, 157-8535, Tokyo, Japan
204 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...